Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer.

Abstract

596Background: Atypical BRAF mutations (aBRAF) represent a rare molecular subtype of metastatic colorectal cancer (mCRC), distinct from BRAFV600E (class I). Preclinical data categorizes aBRAF into ...